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Chronic obstructive pulmonary disease (COPD) is increasing in prevalence, and is predicted to
become the third leading cause of deaths worldwide by 2020. The precise prevalence of COPD
is not known, as many individuals with the disease are left undiagnosed, despite the require-
ment of only simple spirometry testing for disease detection. The major risk factor for the
development of COPD is cigarette smoking, with 90% of deaths from COPD directly attributable
to smoking. Therefore smoking cessation is the most effective means of halting or slowing the
progress of this disease.
This review summarizes and compares the differential characteristics of smokers with COPD
vs. those without COPD in relation to their smoking behavior and quitting attempts, and
discusses the various strategies that can be used to help patients quit and improve their likeli-
hood of long-term smoking cessation. Of the various behavioral interventions available that
can increase the likelihood of smoking cessation, one of the simplest and most effective strat-
egies that physicians can use is simply to advise their patients to quit, particularly if this advice
is combined with informing the patients of their ‘‘lung age’’. We also discuss the pharmaco-
logic therapies used to enhance the likelihood of quitting, including nicotine replacement, bu-
propion SR and varenicline, along with novel nicotine vaccines, which are currently undergoing
clinical trials.
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Tobacco cigarette smoking is the single most preventable
cause of death worldwide and accounts for approximately
438,000 deaths each year in the US.1e3 Smoking contributes
to a number of diseases and has a major impact on four of
the most common causes of death in the US: (i) coronary
heart disease; (ii) cancer (lung, upper aerodigestive tract,
pancreas, stomach, bladder, kidney and cervix); (iii) cere-
bral vascular accidents;4,5 and (iv) chronic obstructive
pulmonary disease (COPD).5
COPD is a disease of increasing prevalence, morbidity and
mortality, but suffers from under-recognition, under-diag-
nosis and under-treatment. It has been defined by the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) as
a ‘‘preventable and treatable disease with some significant
extrapulmonary effects that may contribute to the severity in
individual patients. Its pulmonary component is characterized
by airflow limitation that is not fully reversible. The airflow
limitation is usually progressive and associated with an
abnormal inflammatory response of the lung to noxious
particles or gases’’.6 Since COPD is defined mainly on the basis
of its abnormal physiology, spirometry is essential for diag-
nosis by demonstrating fixed airflow obstruction, i.e., a ratio
of forced expired volume in 1 s (FEV1) to forced vital capacity(FVC) of <70% that does not fully reverse, i.e., does not
increase to70%, after a bronchodilator. GOLD staging of the
severity of COPD is also based on spirometry: mild, moderate,
severe and very severe diseases are defined by FEV1 values of
80%, 50e79%, 30e49% and<30%, respectively. The fact that
spirometry is infrequently performed and that the major
symptom of COPD responsible for limitation of physical
activity, namely exertional dyspnea, does not appear, or is not
recognized, until the airflow obstruction is advanced (or is
incorrectly attributed to some other disease process)
contributes to the under-diagnosis of COPD. Since prevalence
surveys are generally based on self-report of physicians’
diagnoses and COPD is generally under-diagnosed, prevalence
figures are likely to underestimate the true prevalence of
COPD. Therefore, while a US prevalence of 10 million is often
cited,7 the true prevalence is probably much higher. For
example, data from the third National Health and Nutrition
Examination Survey (NHANES III) indicated that 71.7% of those
surveyed who had an FEV1/FVC< 70% (and thus were likely to
have COPD) were never given a diagnosis of COPD by their
physicians; furthermore, 46.2% of those who might have been
classified as having severe COPD by GOLD criteria (FEV1< 50%
predicted) were never diagnosed with COPD.8
COPD often severely limits activities of daily living and
impairs health-related quality of life.9 It is associated with
Smoking cessation in COPD 965significant morbidity and mortality and exerts a huge
economic burden on our healthcare system. US estimates
indicate that annually COPD has accounted for 15.4 million
office visits and 721,000 hospitalizations with estimated
direct and indirect costs (2007) of $42.6 billion.10 In 1990, it
was the twelfth leading cause of disability-adjusted life
years (DALYs) lost worldwide and is projected to become the
fifth leading cause of DALYs lost in 2020. COPD currently
claims 120,000 lives annually in the US.11 The sixth most
common cause of death in the world in 1990, it is projected
to become the third leading cause by the year 2020. In
contrast to downward trends in the death rates due to other
common diseases, such as cardiovascular disease and
cancer, death rates from COPD have been rising steadily over
the past few decades. The latter phenomenon is attributable
to the worldwide epidemic of smoking, as well as to the
decreasing mortality from other common diseases which has
resulted in people in developed countries living longer and
thus being at greater risk for COPD development and
progression. The demographics of COPD have also changed,
as smoking rates among women have increased in recent
decades, leading to a faster increase in COPD prevalence
and mortality among women than men, so that in the year
2000 numerically more women died of COPD than men.7
The major risk factor for COPD, particularly in developed
countries, is cigarette smoking,6,12 the major source of the
‘‘noxious particles or gases’’ that cause the inflammation that
leads to COPD. However, other factors may be contributory in
some individuals, including occupational and environmental
exposures to dusts and fumes,13 infections in early life,14
genetic predisposition,13,15 and asthma.16 Nonetheless,
approximately 90% of all deaths from COPD are attributable to
smoking.17 Just as smoking is the major cause of COPD,
smoking cessation has been shown to be the most effective
strategy for slowing or halting the progression of the
disease.18,19 Nonetheless, it is discouraging that a substantial
percentage of patients with moderate to severe COPD
continue to smoke, ranging from 30.4% to 43.0% in recent
large-scale global clinical trials of patients with moderately
severe to severe disease.20e22 Given the fact that smoking
cessation is the most effective means of favorably modifying
the course of COPD and that approximately a third or more of
patients with advanced COPD continue to smoke, it is obvious
that a major unmet need in the management of the COPD
patient who continues to smoke is the availability of more
effective interventions for smoking cessation in this pop-
ulation of patients with a serious smoking-related disorder.
This paper explores some of the differential characteristics of
smokers with and without COPD relating to their smoking
behavior and their attempts at quitting, and reviews the
effectiveness of various interventions for smoking cessation
specifically in the COPD patient.
Differential characteristics of smokers with
COPD vs. those without
Level of nicotine dependence; difficulty in quitting
and maintaining abstinence
In the Lung Health Study (LHS), an early intervention study
in smokers with mild-to-moderate airflow limitation, it wasassumed that smokers with COPD were more resistant to
smoking cessation intervention than those without COPD
since, despite the fact that smoking was making them sick,
they continued to smoke.23 However, this assumption could
not be tested in the LHS since only smokers with airflow
obstruction were included. Moreover, as indicated below,
this picture is not as simple as was once assumed.
In a general population study in Spain, Jime´nez-Ruiz
et al.24 identified 15% of cases with COPD by spirometry
among 1023 active smokers. Smokers with COPD had higher
nicotine dependence scores than smokers without COPD
(Fagerstro¨m test score 4.77 2.45 with COPD and
3.15 2.38 without COPD, P< 0.001).
A smoking cessation study in the Netherlands reported
only 42% success at 12 months in smokers with COPD,
compared to 68% success in ex-smokers without COPD. The
authors enrolled 38 and 25 participants in the two groups,
respectively. Results at 1-year were point-prevalence
values based on urinary cotinine. Although the success
rates appeared to differ between the groups with and
without COPD, the authors offered no statistical demon-
stration that this was so.25
Bednarek et al.26 recruited 4494 smokers to a study of
smoking cessation. Based on spirometry, 1177 had airways
obstruction and were told they had COPD and that smoking
cessation would halt rapid progression of their lung disease.
Nopharmacologic treatmentwasused.After 1year, about70%
attended a follow-up visit. The smoking cessation rate, vali-
dated by exhaled carbon monoxide, was 16.3% among those
with airways obstruction and 12.0% among those with normal
spirometry (PZ 0.0003). Smoking cessation advice and
spirometry had resulted in a higher cessation rate among
smokers with airways obstruction than among those without
obstruction. The authors concluded, however, that a large
randomized clinical trial is needed to determine more
conclusively whether communicating spirometry findings to
smokers with airflow obstruction has a favorable impact on
smoking cessation.
Stratelis et al.27 enrolled 512 smokers in a study to
demonstrate the value of brief advice and spirometry to
support smoking cessation. Recruits were given spirometry,
smoking cessation advice by a nurse, and a letter from
a physician reinforcing the results of their spirometry, annu-
ally for 3 years. After various exclusions, of those still with the
study after 3 years, 25% of smokers with COPD at baseline
(nZ 119) had been smoke-free for1 year compared to 7% of
those smokers with normal lung function who received the
same level of intervention (nZ 161, P< 0.001).
Use of spirometry (and ‘‘lung age’’) in quitting
Parkes et al.28 assessed the effect on smoking quit rate of
telling patients about their lung age, i.e., the age of the
average healthy individual (adjusted for height and gender)
with the same FEV1 as the patient, based on the Fletchere
Peto diagram (Fig. 1) of the age-related annual rates of
decline in FEV1 in male non-smokers and smokers with
varying susceptibility to the harmful effects of smoking on
lung function.29 Spirometry was performed on 561 current
smokers aged >35 years recruited from the general pop-
ulation. Subjects were randomly divided into two groups:
an intervention group that received their spirometric
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received the raw results of their FEV1. Both groups received
advice to quit and were offered referral to local smoking
cessation services. A new diagnosis of COPD was made in
16% of the participants. Verified quit rates at 12 months
follow-up were 13.6% and 6.4% in the intervention and
control groups, respectively (PZ 0.005). Thus, telling
smokers their ‘‘lung age’’ based on spirometry improved
their likelihood of quitting. Interestingly, however, those
with worse ‘‘lung age’’ (i.e., worse lung function for their
age) were no more (or less) likely to quit than those with
normal ‘‘lung age’’, so that the mechanism for the effec-
tiveness of this intervention is unclear.
Age of smoking initiation, smoking amount,
previous quit attempts
In the above mentioned population study in Spain, smokers
with COPD were more likely to be men (odds ratio [OR]
2.18; 95% confidence interval [CI] 1.21e3.95) and were
more likely to have smoked >30 pack years (OR 3.70; 95% CI
2.42e5.65; P< 0.0001) in an adjusted multiple logistic
regression analysis.24
In the same study,24 35% of smokers with COPD and 39.4%
of smokers without COPD had never tried to quit smoking;
43.6% of smokers with COPD and 42.8% of smokers without
COPD reported 1e3 attempts to quit; 21.5% of smokers with
COPD and 17.8% of smokers without COPD reported >3 quit
attempts.24 These differences were not significant.
Smokers who began at an earlier age are generally
regarded as more likely to have difficulty in quitting. In the
LHS, however, the age participants began smoking was
a non-significant contributor to logistic regressions pre-
dicting 12 month smoking status among both men and
women.30 Furthermore, the lifetime number of years of
smoking was a significant positive predictor of abstinence
at 1 year (OR 1.12; CI 1.02e1.24).31
Smoking-related co-morbidities: cardiovascular,
cancer, osteoporosis, endocrine disturbances
Co-morbid diseases play an important role in COPD
morbidity and prognosis. Co-morbid disorders that areFigure 1 Explaining lung age to participants (adapted from
Parkes et al. 200828).known to be smoking related and occur with greater
frequency in COPD than non-COPD patients include lung
cancer,32 ischemic heart disease,33 congestive heart
failure33 and osteoporosis.34 Lung cancer, the risk of which
is increased in COPD independent of the risk attributable to
tobacco,35 is clearly the driving cause of death when it
occurs in the COPD patient. Co-morbid cardiovascular
disease and hypertension also increase the risk of hospi-
talization and death in COPD, while co-morbid osteopo-
rosis, which is associated with smoking but may also be
a consequence of the systemic inflammation found in
COPD, contributes to the overall morbidity of COPD.
Depression/anxiety
Wilson36 in a review of the topic, reports that there is a high
prevalence of depression in patients with COPD, with 25% of
patients with severe COPD classified as depressed
compared to 19.6% of patients with mild COPD and 17.5% in
a control group. This depression negatively impacts
compliance with smoking cessation. Patients who suffer
from COPD and co-morbid depression are more likely to be
smokers. Indeed, psychiatrists report that smoking appears
to have an antidepressant effect.Impact of smoking cessation (and smoking
reduction) vs. continuing smoking on COPD
Progression of COPD
The LHS, a 5-year early intervention study combining
behavioral therapy and nicotine gum vs. usual care in 3926
smokers with mild-to-moderate airflow limitation due to
COPD, demonstrated that participants who quit smoking and
remained abstinent improved their FEV1 in the year after
quitting and demonstrated a subsequent age-related decline
in FEV1 (mean standard deviation [SD] 31 4 8 mL/year)
that was half the rate among the continuing smokers
(62 55 mL/year).19 This benefit of sustained smoking
cessation in slowing the rate of progressive lung function loss
to a level comparable to that of never smokers persisted for
at least an additional 6 years among the quitters who
remained abstinent (Fig. 2).37 While intermittent quitters
had a rate of lung function decline between that of the sus-
tained quitters and the continuing smokers, the course of
their lung function loss was closer to that of the continuing
smokers. In a separate analysis of data from the LHS,
reduction in the number of cigarettes smoked per day in the
absence of complete cessation did not influence the rate of
decline in lung function unless the percentage reduction was
very marked (>85%), a degree of reduction that was achieved
by only a small minority of the subjects (Fig. 3).38 These
findings underscore the substantial benefits of sustained and
complete smoking cessation in modifying the course of COPD
in contrast to the only limited benefit of partial smoking
reduction. While Hughes et al.39 found that smoking reduc-
tion did not predict future smoking abstinence in the LHS
participants, the role of smoking reduction in promoting
eventual smoking cessation, the best method of harm
reduction, is still uncertain.40
Figure 2 Loss of lung function over 11 years in Lung Health
Study participants with mild-to-moderate COPD in relation to
quitting status (adapted from Anthonisen et al. 200237).
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smoking cessation followed by relapse to smoking and further
attempts to quit smoking during the five years of the study.
The mean annual rate of loss in FEV1% of predicted after year
1 was the smallest for those who quit during year 1 and stayed
abstinent (0.33%/year, 0.05%), intermediate for those
who smoked intermittently during the study (0.58%/year,
0.05%), and greatest for those who continued to smoke
throughout the study (1.18%/year, 0.03%). Quitting
smoking for an interval followed by relapse to smoking
provided a measurable and lasting benefit in comparison to
continuous smoking. The relationship between dose of
cigarettes and average decline in FEV1 during the study for
participants who reported smoking an average of one ciga-
rette per day or more in any month is shown in Fig. 4. The
slope of the curve decreased monotonically with increasing
cigarette dose, suggesting that a given increment in ciga-
rette dose had a more harmful effect in light smokers than it
did in heavy smokers.41
Morbidity
Participants in the LHS were asked each year about
episodes of bronchitis, pneumonia, influenza or chest colds
that resulted in physician visits. These self-reportedFigure 3 One year changes in FEV1 in Lung Health Study
participants, including sustained quitters, intermittent quitters
and continuing smokers with varying degrees of partial smoking
reduction (adapted from Simmons et al. 200538).illnesses were grouped together as lower respiratory
illnesses (LRI), which may be roughly equivalent to exac-
erbations in this population of COPD subjects. Sustained
quitters had fewer LRI than continuing smokers
(PZ 0.0003).42 Moreover, in the year that the LRI occurred,
FEV1 decreased significantly in smokers but did not change
in sustained quitters (PZ 0.0001). Over the 5-year course
of the study, LRI had a significant negative effect on the
rate of FEV1 decline only in smokers. These findings provide
further evidence of the benefits of sustained quitting in
COPD in reducing the frequency of COPD exacerbations, in
addition to prevent the deleterious effect of exacerbations
on the rate of progression of lung function decline.
Mortality
All-cause mortality and mortality due to cardiovascular
disease, lung cancer and other respiratory disease were
determined for participants in the LHS for whom vital status
was followed up to 14.5 years. All-cause mortality was
significantly lower (P< 0.001) in relation to quitting: 6.04 per
1000 patient-years in sustained quitters; 7.77 per 1000
patient-years in intermittent quitters; and 11.09 per 1000
patient-years in continuing smokers.43 With regard to cate-
gorical causes of death, mortality rates were significantly
reduced in relation to quitting smoking for coronary heart
disease (PZ 0.02), cardiovascular disease (P< 0.001), lung
cancer (PZ 0.001) and other causes (PZ 0.03). Clearly,
therefore, the benefits of smoking cessation are manifested
by a reduction in both all-cause mortality and death due to
cardiovascular disease and lung cancer in COPD patients.
Since LHS participants had only mild-to-moderate COPD at
study entry, the impact of smoking cessation on mortality
specifically caused by COPD was probably less than it would
have been in a population with more severe COPD.
Interventions for smoking cessation in the
COPD patient
Physician advice
At office visits with their physician, about 3% of smoking
patients who receive advice to stop (not limited to COPDFigure 4 Five years change in FEV1% predicted by gender as
a function of cigarette dose during the study (adapted from
Murray et al. 199841).
968 D.P. Tashkin, R.P. Murraypatients), have been found to do so, compared with about
1% who quit on their own initiative.44 While this may seem
like a discouraging rate of success, if this small intervention
is consistently followed through a year by the physician it
amounts to a considerable effect at modest expense.
At enrollment in the LHS, 3923 smoking intervention
participants were given an assertive and clear message by
a study physician about their prognosis and its likely effect on
their daily living if they continued to smoke. The study
analyzed the attributes of all of the physicians at all clinical
centers and the outcome of reported smoking status at the
12-month follow-up visit. Absence of physician smoking was
associated with a greater likelihood that participants would
not be smoking at the 12-month visit (smoking MD: 40.8%;
non-smoking MD: 45.4%; P< 0.01), female physicians were
associated with higher quit rates at 12 months (male MD:
42.6%; female MD: 47.2%; P< 0.01), and a younger age of the
physicians in relation to the ageof the participants (physician
age minus participant age) was related to the percent who
quit smoking at 12 months (age difference for male partici-
pants: smoking e 3.15 years, not smoking e 5.05 years; age
difference for female participants: smokinge 3.36 years, not
smokinge 4.67 years; P< 0.0001).45 Due to some limitations
in the data, these analyses were not submitted for publica-
tion and should be interpreted with caution.
What physicians tell patients with COPD about
quitting
Nelson and Hamilton,46 in an observational study of physi-
cians’ interactions with 32 COPD outpatients, found that
the term ‘‘breathing’’ initiated discussion in 56% of visits,
rather than a more specific reference to the nature of the
disease. These discussions focused on the acute nature of
the disease and only in 2% of visits the long-term frequency
of symptoms was addressed. Consequently, in post-visit
interviews, it was found that patients were frequently
misinformed about the severity of their disease.
Telephone quitlines
Tobacco ‘‘quitlines’’ have expanded rapidly in recent years
in the US and elsewhere. In a review of interventions for
smokers who contact telephone quitlines, eight relevant
studies of randomized or quasi-randomized controlled trials
were included.47 These compared multiple call-backs to
a single contact, and found increased quitting in the inter-
vention group (OR 1.41, 95% CI 1.27e1.57). We are not aware
of any studies of telephone quitlines and smoking cessation
in COPD.
Behavioral interventions
In 10 clinical centers, the LHS compared group intervention
and nicotine replacement therapy (NRT; nicotine gum)
(nZ 3923; groups both with and without a short-acting anti-
cholinergic bronchodilator) against no intervention
(nZ 1964) in smokers with early stage COPD.18,31 Biochemi-
cally confirmed smoking abstinence was 35% after 1 year in
the special intervention groups and 9% in the control
group. The study continued to release results until 11 yearsafter randomization.48 The LHS was not designed to enable
the separation between effects of group intervention and
of NRT.
Crowley et al.49 conducted a study in COPD patients
among whom three groups received NRT and self-help but
different levels of individual counseling. These levels
ranged from high-intensity counseling from a physician to
lottery tickets to reward for low carbon monoxide readings.
Few patients in any of the intervention groups exhibited
sustained abstinence and the groups did not differ in this
regard.
Tashkin et al.50 described two randomized groups of
subjects with mild-to-moderate COPD: one with proactive
telephone counseling, individual counseling and bupro-
pion, and the other with proactive telephone counseling,
individual counseling and placebo. The abstinence rate
after 6 months was 9.0% in the control group, which was
the effect of counseling alone in this group of COPD
subjects.
A review by van der Meer et al.51 concluded that there
was insufficient evidence to infer that behavioral inter-
ventions were effective for smoking cessation in COPD. A
review in the following year by the same authors came to
essentially the same conclusions.52
A study comparing individual vs. group interventions in
COPD patients was reported by Christenhusz et al.53 They
randomly allocated 225 patients to a minimal (sometimes
referred to as moderate) intensity individual intervention
(individual counseling and telephone contacts, overall
mean duration 180 min) vs. an intensive group intervention
(group counseling, individual counseling, telephone
contacts and use of bupropion free of charge, overall mean
duration 595 min). Twelve-month abstinence rates were 9%
for the minimal intervention group and 19% for the inten-
sive intervention group, validated by salivary cotinine. The
paper leans away from emphasis on this comparison since
the intensity of counseling in this paper is confounded with
the use of bupropion.Smoking cessation and weight gain
Nides et al.54 reported that in the LHS, females who
maintained abstinence until 12 months had gained 8.4% of
their baseline weight (5.3 kg), whereas males gained 6.7%
(5.5 kg). By 24 months, abstinent women had gained 9.8% of
their baseline weight compared with 6.9% for men. The
continued use of NRT contributed to a delay in part of the
weight gain. The authors concluded that moderate weight
gain is a consequence of smoking cessation. Although the
weight gain observed in the LHS participants who suc-
ceeded in quitting smoking had a slightly negative effect on
FEV1, this was believed to be of minor significance in
relation to the benefits of smoking cessation.55
O’Hara et al.56 extended the findings on weight gain to
abstainers at 5 years in the LHS. Over the 5 years, 33% of
those maintaining abstinence had gained 10 kg in weight or
more. Nineteen percent of women and 7.6% of men had
gained 20% or more of their baseline weight. These changes
in body weight occurred despite the fact that the LHS
smoking cessation intervention had included program
content on anticipating and controlling weight gain.
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Natural support is support from individuals (such as spouses
or significant others) linked to the participants attempting
smoking cessation. Artificially created support is support
from individuals (such as other group members) provided by
an intervention program. In the LHS, participants were
invited to bring with them to the program a significant
other, either a current smoker or non-smoker, who was
willing to support them in the group program. Of partici-
pants who brought a significant other who happened to be
an ex-smoker, 75% of men and 72% of women achieved
abstinence, verified by carbon monoxide in expired air,
after 1 year. Participants supported by a smoker were less
than half as likely to achieve abstinence at 1 year, 34% for
men and 32% for women. Interestingly, natural social
support was clearly beneficial for men in this sample, since
53.4% of men with natural support were still abstinent 1
year after quitting compared to 42.8% of men with no
support. This markedly contrasts with the data for women
for whom 1 year abstinence rates were 44.1 and 46.0% for
those with or without support, respectively. When natural
support was not available, success rates were notably less
positive. The overall intervention success rate in the LHS
was 35% after 1 year.30
Luker et al.57 reviewed publications that addressed the
role of the family in smoking cessation interventions for
individuals with COPD. They identified a number of studies
that specified the characteristics of families of participants,
but few that described the link between family character-
istics and smoking cessation success. They concluded that
no inference could be drawn from the review.
Pharmacologic interventions
Nicotine replacement therapy
Studies on the effect of NRT in smoking cessation among
people with COPD are rare, and are summarized in Table 1,
alongside the efficacy of other pharmacotherapies. Silagy
et al.58 reviewed the effectiveness of NRT for cessation in
smokers in general. They reviewed 123 randomized trials,
and found the overall OR for abstinence with NRT at 6
months or more compared with control was 1.77 (95% CI
1.66e1.88). They found that all forms of NRT were effec-
tive, and the level of additional support provided to the
smoker did not appear to affect the success of NRT,
although it may have facilitated the likelihood of quitting.
Tønnesen et al.59 evaluated sublingual NRT and two
levels of support for smoking cessation in a double-blind,
multicenter, placebo-controlled trial in 370 COPD patients.
Low support consisted of four individual visits and six
telephone calls; high support comprised seven individual
visits and five telephone calls. NRT was significantly more
effective than placebo at 12 months (carbon monoxide in
expired air <10 ppm for 17% vs. 10%, respectively; OR 1.97;
95% CI 1.06e3.67), and there was no difference between
low vs. high behavioral support (11% vs. 16%, respectively;
OR 1.46; 95% CI 0.79e2.68).
The LHS incorporated NRT in its intervention for smoking
cessation a short 3 years after its introduction in the US asa prescription drug. It was used by 3094 participants for
durations ranging from a few days to 5 years. The use of
NRT was unrelated to hospitalizations for cardiovascular
conditions, cardiovascular deaths or other serious side
effects.60 More recently there has been some public
concern about nicotine as a carcinogenic agent. Examina-
tion of 12.5 years of LHS follow-up data has failed to find
evidence of cancers related to the use of NRT.61Bupropion
Bupropion sustained release (SR) was the first non-nicotine-
based pharmacologic agent approved by regulatory
agencies for smoking cessation. In the general smoking
population, bupropion (150 mg twice daily) has been shown
to double the rates of smoking cessation observed with
placebo.62,63 Two subsequent studies examined the effect
of bupropion in promoting smoking abstinence specifically
in subjects with COPD. The first of these studies50 was
a double-blind, randomized, controlled trial of bupropion
150 mg twice daily vs. placebo, administered along with
brief individual counseling, for 12 weeks in 404 individuals
with mild or moderate COPD defined according to the
American Thoracic Society criteria (FEV1/FVC 70%,
FEV1 50% predicted [mild severity] or FEV1 35e49% pre-
dicted [moderate severity]) who smoked 15 cigarettes/
day. Continuous abstinence rates from 4 to 26 weeks were
significantly higher in subjects receiving bupropion (16%)
than in those taking placebo (9%) (P< 0.05). Symptoms of
tobacco craving and withdrawal were also significantly
reduced in those receiving bupropion. However, results
from 4 weeks to 12 months (not presented in the original
report) no longer showed a significant difference in
continuous smoking abstinence between the bupropion
group (10%) and the placebo group (8%).52
A subsequent study64 compared the efficacy of bupropion
SR (150 mg twice daily) with that of the antidepressant
nortriptyline (75 mg once daily) administered with brief
smoking cessation counseling for 12 weeks in a double-
dummy randomized placebo-controlled trial in 255 adults
either ‘‘at risk’’ for COPD (i.e., smokers without airflow
limitation; nZ 111) or with mostly mild-to-moderate COPD
by GOLD criteria (nZ 144). In patients with COPD, bupropion
was significantly efficacious in achieving sustained absti-
nence from 4 to 26 weeks (27.3%) compared with placebo
(8.3%) (PZ 0.02). Interestingly, while similar 26-week
abstinence rates were noted with bupropion therapy in the
subgroup ‘‘at risk’’ for COPD (28.6%), the placebo-treated
subjects in the ‘‘at risk’’ category showed substantially
higher abstinence rates (22.0%) than those with COPD, so
that no significant efficacy effect of bupropion could be
demonstrated in the ‘‘at risk’’ subjects. While nortriptyline
also showed higher long-term abstinence rates in both the
COPD and ‘‘at risk’’ subjects (21.2% and 32.1%, respectively),
no significant differences from placebo were noted in either
the COPD patients (PZ 0.07) or in those at risk for COPD
(PZ 0.59). Insomnia was the most commonly reported side
effect of bupropion. Bupropion has also been shown to lower
the threshold for seizures, so that the drug is contraindicated
in patients with a seizure history or at increased risk for
seizure activity.
Table 1 A summary of the efficacy of different non-pharmacologic and pharmacologic interventions in patients by COPD
status.
Intervention Reference Follow-up Cessation rate (%) Control (%) COPD Status Counseling
Minimal advice
from GP
44 None 3.0a 1.0a General smoking
population
None
Being informed
of COPD status
26 1 year 16.3 12.0 General smoking
population
Brief counseling
Being informed
of COPD status
27 3 years 25.0 7.0 General smoking
population
Brief counseling/yearly
reinforcement by GP
Being informed
of ‘‘lung age’’
28 1 year 13.6 6.4 General smoking
population
Brief counseling/referral
to smoking cessation services
NRT 18,31 1 & 5 years 35.0 9.0 Mild-moderate Group intervention
48 11 years 21.9 6.0 Mild-moderate Group intervention
59 6 months 23.0 10.0 All stages Low vs. high support
1 yearb 17.0 10.0 All stages Low vs. high support
Bupropion SR 50 6 months 16.0 9.0 Mild-moderate Individual
1 year 10.0 8.0 Mild-moderate Individual
53 1 year 19.0 9.0 Moderate-severe Minimal vs. intensive
64 6 months 27.3 8.3 Mild-moderate Brief counseling
6 months 28.6 22.0 At risk of COPD Brief counseling
69 1 year 16.1 8.4 General smoking
populationc
Brief counseling
70 1 year 14.6 10.3 General smoking
populationc
Brief counseling
Varenicline 69 1 year 21.9 8.4 General smoking
populationc
Brief counseling
70 1 year 23.0 10.3 General smoking
populationc
Brief counseling
Nortriptyline 64 6 months 21.2 8.3 Mild-moderate Brief counseling
6 months 32.1 22.0 At risk of COPD Brief counseling
NRTZ Nicotine Replacement Therapy; SRZ Sustained Release.
a Proportion of patients who quit in a given year.
b Data from GlaxoSmithKline (not presented in published paper).
c Subjects with severe COPD excluded.
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it may be related to its action in inhibiting neuronal reup-
take of dopamine and norepinephrine in the nucleus
accumbens and nucleus ceruleus, respectively, which may
help to reduce craving and attenuate withdrawal symp-
toms.65 In addition, it has been shown in rats to be a non-
competitive functional inhibitor of acetylcholine receptors,
a property that could hypothetically counteract nicotine
dependence.66
Varenicline
The a4b2 nicotinic acetylcholine receptor (nAChR) subtype
is believed to play a role in the reinforcing effects of
nicotine that are modulated by dopamine release in the
nucleus accumbens.67 This concept led to the development
of varenicline, a high-affinity a4b2 partial agonist, with the
expectation that this compound could both stimulate
dopamine release to reduce craving and withdrawal and at
the same time, through its partial antagonist property,
block the binding and resultant reinforcing effects of
nicotine derived from smoking.68 Randomized, double-blind
controlled clinical trials have been carried out comparing
the efficacy of varenicline (titrated to 1 mg twice daily)
with both placebo and the active agent, bupropion (150 mgtwice daily), administered for 12 weeks, along with brief
smoking cessation counseling, and followed for a full
year.69,70 In one of these trials involving 1025 healthy
smokers, varenicline resulted in continuous abstinence
rates from 9 through 52 weeks of 21.9% vs. 8.4% for placebo
(P< 0.001) and 16.1% for bupropion (PZ 0.057) (Fig. 5).69
In a similarly designed study in 1027 smokers, varenicline
resulted in continuous abstinence rates from 9 through 52
weeks of 23% vs. 10.3% for placebo (P< 0.001) and 14.6% for
bupropion (PZ 0.004).70 Nausea was the most common side
effect of varenicline in both trials, occurring in 28.1e29.4%
of the participants. Thus, varenicline appears to be more
than twice as effective as placebo and 36e57% more
effective than bupropion in promoting long-term (52-week)
abstinence in adult smokers. Moreover, in both of these
trials, varenicline reduced craving and withdrawal and, for
those who smoked while receiving the drug, it also reduced
smoking satisfaction, consistent with its hypothesized
mechanism of action in attenuating withdrawal after
smoking cessation and inhibiting the reinforcing effects of
nicotine during relapse. While the FDA has received post-
marketing reports of depressed mood, suicidal ideation and
occasional suicidal behavior in patients taking varenicline,
the role of varenicline in these cases is not clear, given the
fact that smoking cessation itself may be associated with
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less, the FDA has advised health professionals to monitor
patients taking varenicline for behavior and mood changes.
Smoking cessation has been identified by GOLD as the
most important intervention in the prevention and treat-
ment of COPD.6 Unfortunately, however, continuing
smokers with COPD appear to have particular difficulty in
achieving sustained smoking cessation, even with the aid of
pharmacologic agents for treating nicotine dependence.50
In view of the greater success of varenicline in treating
nicotine dependence in smokers in the general population
compared with other currently available therapies, a clin-
ical trial of varenicline targeted specifically at continuing
smokers with COPD was deemed warranted. To this end,
a randomized, double-blind, placebo-controlled multi-
center study of varenicline administered for 12 weeks for
a total study duration of 52 weeks was initiated in 500
subjects with spirometrically confirmed COPD. The
recruitment goal for this study was recently fulfilled and
the study is ongoing with expected completion by mid-
2009. More information about this study (registration
number NCT00285012) is available at clinicaltrials.gov.
Combination pharmacotherapy for nicotine
dependence
A recently published meta-analysis of combination therapy
for smoking cessation included studies that had large
sample sizes (nZ200), tested first-line therapies and
were double-blind randomized controlled trials lasting
one year or more.71 A literature search covered the years
1994e2007. Five clinical trials met the inclusion criteria.
These five trials combined nicotine patch and nicotine gum
(2 trials), nicotine patch and nicotine nasal spray, nicotine
patch and bupropion SR, and nicotine patch and nicotine
inhaler. None of these studies was specific to COPD
patients. The aggregated relative risk of abstinence
comparing combination with single treatment groups was
statistically significant at 3, 6, and 12 months. At 12 months
it was 1.58 (95% CI 1.25e1.99). In a recent revision of the
smoking cessation guidelines from the US Public HealthFigure 5 CO-confirmed continuous abstinence rates for
varenicline vs. bupropion vs. placebo (adapted from Gonzales
et al. 200669).Service, physicians are urged to consider medication
combinations with proven effectiveness.72
Nicotine vaccines
Two nicotine vaccines are currently under clinical develop-
ment as biologic therapeutic aids to smoking cessation. Both
products NicVAX (Nabi Pharmaceuticals) and CYTO02-
NicQb (Novartis) are conjugate vaccines that stimulate the
production of antibodies that bind to smoking-derived nico-
tine in the circulation. The resultant nicotine-antibody
complexes are too large to cross the bloodebrain barrier,
thus preventing nicotine from reaching nicotinic receptors in
the brain. As a result, the addictive properties of nicotine
would be eliminated, thereby promoting smoking cessation
and preventing relapse. A theoretical advantage of nicotine
vaccines is that they would result in ‘‘enforced compliance’’
since, once injected by the healthcare provider, the smokers
would not be required to self-administer the medication.
Both products have been evaluated in Phase II trials involving
serial intramuscular injections of the vaccine at intervals of 4
weeks or more with serial measurement of antibody levels
and monitoring of smoking cessation and continuing absti-
nence. Only preliminary data have been presented in news
releases and abstract form. In a placebo-controlled trial of
NicVAX thatenrolled 301 heavy smokers, among the top 30%
of antibody responders, 24.6% showed continuous abstinence
between weeks 19 and 26, compared with 13.0% for the 100
patients receiving placebo (PZ 0.04) (May 9, 2007; http://
www.nabi.com). However, the quit rate for the 70% of
patients who did not develop a high antibody response was
not different from placebo. The challenge for further
development of these vaccines is to boost the immune
response so that higher and sustained levels of antibodies can
be produced to ‘‘soak up’’ circulating nicotine.Other interventions: hypnosis, acupuncture,
exercise
The Cochrane collaboration review of smoking cessation in
COPD found that hypnosis and acupuncture were essentially
not effective as cessation aids.51 Exercise is a more positive
activity in overall quality of life, but studies demonstrating
its value in smoking cessation are scarce.Conclusions
COPD is an ever increasing burden on health budgets, often
goes undiagnosed and is associated with several smoking-
related co-morbidities such as lung cancer, ischemic heart
disease, congestive heart failure and osteoporosis. It is
therefore of the utmost importance that physicians ques-
tion patients at risk about any respiratory symptoms and
take appropriate action with respect to diagnosis (perform
spirometry) and management.6
As cigarette smoking is the major risk factor for
COPD, and as patients with COPD reportedly find it harder
to quit, it is important that physicians offer the most
efficacious means to encourage smoking cessation. We
suggest a suitable strategy in Box 1 that would be useful
Box 1. Advice for the practicing physician,
irrespective of whether their patients have
COPD or another smoking-related illness.
Do as many of the following as are feasible:
 At every encounter, ask the patient if he/she is
smoking. Chart the response.
 Advise all patients who smoke to quit. As obvious
as this seems, patients do not hear what you tell
them, but rather what it is they want to hear. They
need a clear, assertive, non-judgmental message
to stop smoking. Do not let the patient leave your
office saying, ‘‘The doctor did not tell me to quit
smoking’’.
 Measure your patients’ carbon monoxide in
expired air. A reading above 10 ppm indicates
current smoking. This result will not only verify
their smoking status but will indicate to them in
a more graphic way what it is that they are
breathing out.
 Perform office spirometry or order spirometry.
Unknown diagnoses of COPD are made this way.
Interpret the results for the patient. Express the
spirometry result in terms of ‘‘lung age’’.
 Ask the patients if they are ready to quit and their
history of quit attempts.
 Negotiate a target Quit Day in the near future. You
can be sensitive to their degree of readiness, but
with your status as their physician, you could
effectively impose a Quit Day when quitting is
a high priority.
 Have your office staff follow-up by phone on or
shortly after Quit Day to remind your smoking
patients to quit and assess their progress.
 Prescribe pharmacological support: NRT, bupro-
pion SR or varenicline, as appropriate.
 Refer the patient to a behavioral support program
in the community. Your staff can identify a list of
such services. The Local Lung Association or Cancer
Society are good places to start. Such programs are
resource-intensive and not suitable to conduct from
your office.
 When appropriate, a telephone quitline can be
recommended.
 Schedule follow-up appointments to address your
patients’ smoking status.
972 D.P. Tashkin, R.P. Murrayin the treatment of all smokers, both with and without
COPD.
Although physician advice and communicating clinical
facts to patients, such as their spirometry results and lung
age, have some efficacy in encouraging patients to quit
smoking, a growing number of studies indicate that the
benefits of behavioral therapies in promoting smoking
cessation can be enhanced by the use of pharmacologic
therapies such as nicotine replacement, bupropion SR and
varenicline, including medication combinations with proven
effectiveness. While these therapies have also been foundto increase long-term abstinence rates, it is imperative that
the physician continues to encourage cessation and main-
tenance of abstinence in order to slow the rate of
progressive lung function loss in those with COPD.
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